The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE‐TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial.

[1]  C. Mathieu,et al.  Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) , 2020, Diabetologia.

[2]  B. Lewis,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2020 .

[3]  M. Pfeffer,et al.  Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[5]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[6]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[7]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[8]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.

[10]  J. Eriksson,et al.  Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study , 2019, Diabetes, obesity & metabolism.

[11]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[12]  R. Herings,et al.  How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study , 2019, Diabetes, obesity & metabolism.

[13]  Elizabeth M Lamos,et al.  Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes , 2018, Expert opinion on pharmacotherapy.

[14]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[15]  K. Mahaffey,et al.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. , 2018, The lancet. Diabetes & endocrinology.

[16]  Deepak L. Bhatt,et al.  DECLARE‐TIMI 58: Participants’ baseline characteristics , 2018, Diabetes, obesity & metabolism.

[17]  E. Wittbrodt,et al.  Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. , 2018, The American journal of managed care.

[18]  K. Bell,et al.  Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting , 2018, Journal of medical economics.

[19]  C. Coleman,et al.  Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. , 2018, Journal of diabetes and its complications.

[20]  B. Zinman,et al.  Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial , 2018, European heart journal.

[21]  Frank B. Hu,et al.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications , 2018, Nature Reviews Endocrinology.

[22]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[23]  B. Zinman,et al.  Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. , 2017, Circulation.

[24]  N. Maniadakis,et al.  Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece , 2017, Clinical Drug Investigation.

[25]  B. Carstensen,et al.  Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study , 2017, Diabetes, obesity & metabolism.

[26]  B. Carstensen,et al.  Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. , 2017, The Lancet Diabetes and Endocrinology.

[27]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[28]  S. Zhai,et al.  Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus , 2017, Current medical research and opinion.

[29]  M. Baxter,et al.  Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[30]  S. Zhai,et al.  Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China , 2016, PloS one.

[31]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[32]  N. Maniadakis,et al.  Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece , 2016, Clinical Drug Investigation.

[33]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[34]  Darren K Mcguire,et al.  Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus , 2016, Diabetes & vascular disease research.

[35]  I. C. Team.  Type 2 Diabetes in Adults: Management , 2015 .

[36]  M. Charokopou,et al.  Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective , 2015, BMC Health Services Research.

[37]  P. McEwan,et al.  Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model , 2015, Cost Effectiveness and Resource Allocation.

[38]  M. Charokopou,et al.  The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[39]  M. Ekman,et al.  Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. , 2015, Primary care diabetes.

[40]  M. Charokopou,et al.  Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  M. Charokopou,et al.  Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  M. Charokopou,et al.  The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[43]  M. Charokopou,et al.  Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  P. McEwan,et al.  Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands , 2014, Clinical Drug Investigation.

[45]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[46]  R. R. Holman,et al.  UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.

[47]  J. Gagliardino,et al.  Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina , 2013, Health Economics Review.

[48]  P. McEwan,et al.  Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany , 2012, Clinical Drug Investigation.

[49]  P. McEwan,et al.  Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. , 2012, Primary care diabetes.

[50]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[51]  K. Kolasa,et al.  The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. , 2012, Diabetes technology & therapeutics.

[52]  Diederick E. Grobbee,et al.  The global burden of diabetes and its complications: an emerging pandemic , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[53]  M. Fowler.  Microvascular and Macrovascular Complications of Diabetes , 2008, Clinical Diabetes.

[54]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[55]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[56]  M. Faisal,et al.  Microvascular and macrovascular complications of diabetes , 2012 .